CR20200467A - Agentes anticuerpos anti-cd25 - Google Patents

Agentes anticuerpos anti-cd25

Info

Publication number: CR20200467A
Authority: CR; Costa Rica
Prior art keywords: antibody; antibodies; antibody agents; binding; sequences
Prior art date: 2018-03-13

Application number

CR20200467A

Other languages

English (en)

Inventor

Mark Brown

Anne Goubier

Corzo Beatriz Goyenechea

Kevin Moulder

Josephine Salimu

Sergio Quezada

James Geoghegan

Bianka Prinz

Pascal Merchiers

Original Assignee

Cancer Research Tech Ltd

Tusk Therapeutics Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-03-13

Filing date

2019-03-13

Publication date

2020-11-17

2018-03-13 Priority claimed from PCT/EP2018/056312 external-priority patent/WO2018167104A1/en

2018-03-13 Priority claimed from GBGB1804027.9A external-priority patent/GB201804027D0/en

2018-03-13 Priority claimed from GBGB1804029.5A external-priority patent/GB201804029D0/en

2018-03-13 Priority claimed from GBGB1804028.7A external-priority patent/GB201804028D0/en

2019-03-13 Application filed by Cancer Research Tech Ltd, Tusk Therapeutics Ltd filed Critical Cancer Research Tech Ltd

2020-11-17 Publication of CR20200467A publication Critical patent/CR20200467A/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/05—Epstein-Barr virus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Gastroenterology & Hepatology (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Toxicology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Oncology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Hematology (AREA)
Tropical Medicine & Parasitology (AREA)
Cell Biology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CR20200467A 2018-03-13 2019-03-13 Agentes anticuerpos anti-cd25 CR20200467A (es)

Applications Claiming Priority (10)

Application Number	Priority Date	Filing Date	Title
US201862642230P	2018-03-13	2018-03-13
US201862642218P	2018-03-13	2018-03-13
US201862642243P	2018-03-13	2018-03-13
US201862642248P	2018-03-13	2018-03-13
US201862642232P	2018-03-13	2018-03-13
PCT/EP2018/056312 WO2018167104A1 (en)	2017-03-17	2018-03-13	Fc-optimized anti-cd25 for tumour specific cell depletion
GBGB1804027.9A GB201804027D0 (en)	2018-03-13	2018-03-13	Anti-CD25 antibody agents
GBGB1804029.5A GB201804029D0 (en)	2018-03-13	2018-03-13	Anti-CD25 antibody agents
GBGB1804028.7A GB201804028D0 (en)	2018-03-13	2018-03-13	Anti-CD25 antibody agents
PCT/EP2019/056248 WO2019175216A1 (en)	2018-03-13	2019-03-13	Anti-cd25 for tumour specific cell depletion

Publications (1)

Publication Number	Publication Date
CR20200467A true CR20200467A (es)	2020-11-17

Family

ID=67903878

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
CR20200465A CR20200465A (es)	2018-03-13	2019-03-13	Agentes anticuerpos anti-cd25
CR20200466A CR20200466A (es)	2018-03-13	2019-03-13	Agentes anticuerpos anti-cd25
CR20200467A CR20200467A (es)	2018-03-13	2019-03-13	Agentes anticuerpos anti-cd25

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
CR20200465A CR20200465A (es)	2018-03-13	2019-03-13	Agentes anticuerpos anti-cd25
CR20200466A CR20200466A (es)	2018-03-13	2019-03-13	Agentes anticuerpos anti-cd25

Country Status (14)

Country	Link
US (11)	US11814434B2 (es)
EP (8)	EP3765505B1 (es)
JP (8)	JP7451415B2 (es)
KR (3)	KR20200131286A (es)
CN (8)	CN112020516B (es)
AU (3)	AU2019233581B2 (es)
BR (3)	BR112020016501A2 (es)
CA (3)	CA3088659A1 (es)
CR (3)	CR20200465A (es)
MA (1)	MA51993A (es)
PE (3)	PE20210289A1 (es)
SG (3)	SG11202008699WA (es)
TW (3)	TW202003034A (es)
WO (8)	WO2019175224A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11371066B2 (en)	2015-07-13	2022-06-28	Modular Genetics, Inc.	Generation of acyl alcohols
CA3020204A1 (en) *	2016-04-07	2017-10-12	Cancer Research Technology Limited	Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion
CN108795858A (zh) *	2017-04-28	2018-11-13	深圳宾德生物技术有限公司	高抗癌活性t细胞的筛选方法和应用
US11814434B2 (en)	2018-03-13	2023-11-14	Tusk Therapeutics Ltd.	Anti-CD25 for tumour specific cell depletion
EP3972997A1 (en) *	2019-05-20	2022-03-30	Institut National de la Santé et de la Recherche Médicale (INSERM)	Novel anti-cd25 antibodies
TWI877278B (zh)	2019-12-30	2025-03-21	美商思進公司	以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
CN115397860B (zh)	2020-05-14	2025-06-13	江苏恒瑞医药股份有限公司	抗cd25抗体、其抗原结合片段及其医药用途
US11124568B1 (en) *	2020-08-19	2021-09-21	Vitruviae LLC	CD3/CD25 antibodies for neuro-immune diseases
WO2022104009A1 (en) *	2020-11-13	2022-05-19	Rubryc Therapeutics, Inc.	Cd25 antibodies
EP4247497A1 (en) *	2020-11-20	2023-09-27	Institut National de la Santé et de la Recherche Médicale (INSERM)	Anti-cd25 antibodies
EP4247496A1 (en) *	2020-11-20	2023-09-27	Institut National de la Santé et de la Recherche Médicale (INSERM)	Anti-cd25 antibodies
EP4255929A2 (en)	2020-12-02	2023-10-11	Vib Vzw	An ltbr agonist in combination therapy against cancer
US20240307541A1 (en)	2021-02-02	2024-09-19	Rakuten Medical, Inc.	Methods for local and systemic treatment of cancers, tumors and tumor cells
WO2022184615A1 (en)	2021-03-01	2022-09-09	F. Hoffmann-La Roche Ag	Novel biomarkers and uses thereof
WO2023016455A1 (zh)	2021-08-09	2023-02-16	南京诺艾新生物技术有限公司	重组抗人cd25抗体及其应用
CA3228786A1 (en) *	2021-08-25	2023-03-02	Ibio, Inc.	Anti-cd25 antibody
CN117916266A (zh)	2021-09-02	2024-04-19	弗哈夫曼拉罗切有限公司	用于治疗aml的抗体
AU2022337286A1 (en) *	2021-09-03	2024-02-29	Novarock Biotherapeutics, Ltd.	Bispecific binding proteins that bind cd137 and a tumor associated antigen
US20250154268A1 (en)	2022-01-17	2025-05-15	Nona Biosciences (Suzhou) Co., Ltd.	Antibody targeting cd25, and preparation method therefor and use thereof
WO2023208990A1 (en)	2022-04-26	2023-11-02	F. Hoffmann-La Roche Ag	Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist,
CN115197321B (zh) *	2022-06-02	2023-08-18	四川大学	靶向cd25的抗体及其用途
CN115181182B (zh) *	2022-06-13	2024-03-29	南京融捷康生物科技有限公司	一种人源化的抗cd25的单域抗体及其应用
CN115181181B (zh) *	2022-06-13	2024-03-29	南京融捷康生物科技有限公司	一种抗cd25的单域抗体及其应用
WO2024006965A1 (en) *	2022-06-30	2024-01-04	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Cd25-specific antibodies and uses thereof
WO2024040194A1 (en)	2022-08-17	2024-02-22	Capstan Therapeutics, Inc.	Conditioning for in vivo immune cell engineering
WO2024088987A1 (en)	2022-10-26	2024-05-02	F. Hoffmann-La Roche Ag	Combination therapy for the treatment of cancer
CN118240080A (zh) *	2022-12-22	2024-06-25	深圳市福元生物科技有限公司	一种cd25单域抗体、人源化抗体、及制备方法
CN116004636B (zh) *	2023-01-10	2024-03-12	广西师范大学	一种不结合红细胞的差异化cd47核酸适体及其应用
CN120584138A (zh)	2023-02-06	2025-09-02	豪夫迈·罗氏有限公司	组合疗法及其用途
AU2024234615A1 (en) *	2023-03-14	2025-08-21	Odyssey Therapeutics, Inc.	Anti-cd25 antigen-binding proteins and uses thereof
EP4692351A1 (en)	2023-03-29	2026-02-11	Daiichi Sankyo Company, Limited	Anti-cd25 antibody and anti-cd25 antibody-drug conjugate
WO2024213046A1 (en) *	2023-04-11	2024-10-17	Suzhou Transcenta Therapeutics Co., Ltd.	Anti-cd25 antibody and uses thereof
CN121666232A (zh)	2023-05-31	2026-03-13	开普斯坦治疗公司	脂质纳米颗粒制剂和组合物
WO2025076113A1 (en)	2023-10-05	2025-04-10	Capstan Therapeutics, Inc.	Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en)	2023-10-05	2025-04-10	Capstan Therapeutics, Inc.	Constrained ionizable cationic lipids and lipid nanoparticles
US20250215087A1 (en)	2023-12-29	2025-07-03	Bristol-Myers Squibb Company	Combination therapy of kras inhibitor and treg depleting agent
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof
WO2025179294A2 (en)	2024-02-22	2025-08-28	Capstan Therapeutics, Inc.	Immune engineering amplification
WO2025217452A1 (en)	2024-04-11	2025-10-16	Capstan Therapeutics, Inc.	Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en)	2024-04-11	2025-10-16	Capstan Therapeutics, Inc.	Ionizable cationic lipids and lipid nanoparticles
WO2026006708A2 (en) *	2024-06-27	2026-01-02	Odyssey Therapeutics, Inc.	Anti-cd25 antigen-binding proteins and uses thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4208479A (en)	1977-07-14	1980-06-17	Syva Company	Label modified immunoassays
US4578335A (en) *	1984-05-21	1986-03-25	Immunex Corporation	Interleukin 2 receptor
NZ540555A (en)	2002-11-15	2008-04-30	Genmab As	Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
US20050181375A1 (en)	2003-01-10	2005-08-18	Natasha Aziz	Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
CA2516028C (en)	2003-02-14	2012-10-16	University Of Southern California	Conjugates comprising a cancer targeting molecule linked to a liver-expressed chemokine
WO2005123780A2 (en)	2004-04-09	2005-12-29	Protein Design Labs, Inc.	Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
GB0409799D0 (en)	2004-04-30	2004-06-09	Isis Innovation	Method of generating improved immune response
EP1814568A4 (en)	2004-10-29	2009-08-12	Univ Southern California	COMBINATION IMMUNOTHERAPY AGAINST CANCER WITH COSTIMULATORY MOLECULES
GB0507696D0 (en)	2005-04-15	2005-05-25	Novartis Ag	Organic compounds
CA2656700A1 (en)	2006-07-06	2008-01-10	Merck Patent Gesellschaft Mit Beschraenkter Haftung	Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
HRP20140081T1 (hr)	2006-08-18	2014-03-28	Novartis Ag	Prlr-specifiäśna antitijela i njihova uporaba
EP1997832A1 (en) *	2007-05-29	2008-12-03	Ganymed Pharmaceuticals AG	Monoclonal antibodies against Claudin-18 for treatment of cancer
RU2391401C2 (ru)	2008-02-12	2010-06-10	Общество с ограниченной ответственностью "Лаборатория клеточного мониторинга"	СПОСОБ ПОЛУЧЕНИЯ ПОПУЛЯЦИИ CD4+CD25+Foxp3+ Т-ЛИМФОЦИТОВ ЧЕЛОВЕКА ex vivo, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
DK2356270T3 (da) *	2008-11-07	2016-12-12	Fabrus Llc	Kombinatoriske antistofbiblioteker og anvendelser deraf
US8642292B2 (en) *	2009-09-22	2014-02-04	Probiogen Ag	Process for producing molecules containing specialized glycan structures
WO2011077245A2 (en)	2009-12-23	2011-06-30	Fondazione Centro San Raffaele Del Monte Tabor	Compositions
AR079944A1 (es)	2010-01-20	2012-02-29	Boehringer Ingelheim Int	Anticuerpo neutralizante de la actividad de un anticoagulante
EP2378287A1 (en) *	2010-04-15	2011-10-19	TXCell	New method for isolating Tr1 cells
KR20130048242A (ko)	2010-07-22	2013-05-09	더 리젠츠 오브 더 유니버시티 오브 캘리포니아	항-종양 항원 항체 및 이용 방법
US9682143B2 (en)	2012-08-14	2017-06-20	Ibc Pharmaceuticals, Inc.	Combination therapy for inducing immune response to disease
CN105377892A (zh) *	2013-03-15	2016-03-02	艾伯维生物技术有限公司	抗cd25抗体及其用途
EP3421495A3 (en) *	2013-03-15	2019-05-15	Xencor, Inc.	Modulation of t cells with bispecific antibodies and fc fusions
BR112015023086A2 (pt)	2013-03-15	2017-11-21	Abbvie Biotechnology Ltd	anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, métodos para produção de um anticorpo anti-cd25 ou fragmento ligante anti cd25, para prevenção de rejeição de órgãos transplantados e para tratamento de uma doença.
JP6824735B2 (ja) *	2013-06-06	2021-02-03	ピエール、ファーブル、メディカマン	抗Ｃ１０ｏｒｆ５４抗体およびその使用方法
WO2015109212A1 (en) *	2014-01-17	2015-07-23	Pfizer Inc.	Anti-il-2 antibodies and compositions and uses thereof
ES2716685T3 (es)	2014-01-24	2019-06-14	Dana Farber Cancer Inst Inc	Moléculas de anticuerpo para PD-1 y usos de las mismas
GB201403775D0 (en) *	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
JP2017522311A (ja)	2014-07-16	2017-08-10	ジェネンテック，インコーポレイテッド	Ｔｉｇｉｔ阻害剤及び抗癌剤を使用する癌の治療方法
JP6986965B2 (ja) *	2014-07-22	2021-12-22	アポロミクスインコーポレイテッド	抗ｐｄ−１抗体
CA2957387A1 (en)	2014-08-07	2016-02-11	Haruki Okamura	Therapeutic agent for cancer which comprises combination of il-18 and molecule-targeting antibody
US11147652B2 (en)	2014-11-13	2021-10-19	Align Technology, Inc.	Method for tracking, predicting, and proactively correcting malocclusion and related issues
RU2753902C2 (ru) *	2014-11-20	2021-08-24	Ф.Хоффманн-Ля Рош Аг	Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
HUE050596T2 (hu) *	2014-11-21	2020-12-28	Bristol Myers Squibb Co	Antitestek CD73 ellen és azok felhasználásai
AR103268A1 (es) *	2014-12-23	2017-04-26	Bristol Myers Squibb Co	Anticuerpos contra tigit
US10227408B2 (en)	2015-02-19	2019-03-12	Compugen Ltd.	Anti-PVRIG antibodies and methods of use
CA2980390A1 (en) *	2015-03-23	2016-09-29	Bayer Pharma Aktiengesellschaft	Anti-ceacam6 antibodies and uses thereof
KR102876923B1 (ko) *	2015-10-23	2025-10-28	화이자 인코포레이티드	항-il-2 항체 및 조성물 및 이의 용도
US20170204154A1 (en)	2016-01-20	2017-07-20	Delinia, Inc.	Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
IL295230A (en) *	2016-03-04	2022-10-01	Bristol Myers Squibb Co	Combination therapy with anti-cd73 antibodies
WO2017148424A1 (zh) *	2016-03-04	2017-09-08	四川科伦博泰生物医药股份有限公司	一种pdl-1抗体、其药物组合物及其用途
CA3020204A1 (en)	2016-04-07	2017-10-12	Cancer Research Technology Limited	Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion
KR102495601B1 (ko) *	2016-06-10	2023-02-06	리제너론 파마슈티칼스 인코포레이티드	항-gitr 항체 및 그것의 사용
JP6831651B2 (ja)	2016-07-04	2021-02-17	川崎重工業株式会社	ワークの袋詰め装置
WO2018089420A1 (en)	2016-11-08	2018-05-17	Delinia, Inc.	Il-2 variants for the treatment of autoimmune diseases
US11879014B2 (en)	2017-03-17	2024-01-23	Tusk Therapeutics Ltd.	Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
US11119165B2 (en)	2017-06-28	2021-09-14	North Carolina State University Office of Research Commercialization	Photonic band-gap resonator for magnetic resonance applications
JP7225135B2 (ja)	2017-07-06	2023-02-20	タスクセラピューティクスリミテッド	腫瘍特異的細胞枯渇のための化合物及び方法
UA129536C2 (uk)	2018-03-13	2025-05-28	Туск Терап'Ютікс Лтд	Анти-cd25 для виснаження пухлиноспецифічних клітин
US11814434B2 (en)	2018-03-13	2023-11-14	Tusk Therapeutics Ltd.	Anti-CD25 for tumour specific cell depletion
KR20200003558A (ko)	2018-07-02	2020-01-10	휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피.	용지 슬립을 방지하기 위한 급지장치 및 이를 포함하는 화상형성장치
KR102080909B1 (ko)	2018-07-06	2020-02-24	한국수력원자력 주식회사	원자로의 해체 시스템

2019
- 2019-03-13 US US16/979,930 patent/US11814434B2/en active Active
- 2019-03-13 EP EP19709957.5A patent/EP3765505B1/en active Active
- 2019-03-13 WO PCT/EP2019/056258 patent/WO2019175224A1/en not_active Ceased
- 2019-03-13 CN CN201980019256.8A patent/CN112020516B/zh active Active
- 2019-03-13 CR CR20200465A patent/CR20200465A/es unknown
- 2019-03-13 WO PCT/EP2019/056249 patent/WO2019175217A1/en not_active Ceased
- 2019-03-13 EP EP19711075.2A patent/EP3765510A1/en active Pending
- 2019-03-13 BR BR112020016501-8A patent/BR112020016501A2/pt unknown
- 2019-03-13 KR KR1020207029205A patent/KR20200131286A/ko not_active Withdrawn
- 2019-03-13 EP EP19709955.9A patent/EP3765503B1/en active Active
- 2019-03-13 PE PE2020001320A patent/PE20210289A1/es unknown
- 2019-03-13 CA CA3088659A patent/CA3088659A1/en not_active Abandoned
- 2019-03-13 US US16/979,935 patent/US11697688B2/en active Active
- 2019-03-13 WO PCT/EP2019/056260 patent/WO2019175226A1/en not_active Ceased
- 2019-03-13 JP JP2020547399A patent/JP7451415B2/ja active Active
- 2019-03-13 US US16/979,929 patent/US11802161B2/en active Active
- 2019-03-13 CN CN201980019257.2A patent/CN112218891B/zh active Active
- 2019-03-13 CR CR20200466A patent/CR20200466A/es unknown
- 2019-03-13 JP JP2020547326A patent/JP7563978B2/ja active Active
- 2019-03-13 CN CN201980019234.1A patent/CN112074536B/zh active Active
- 2019-03-13 KR KR1020207029221A patent/KR102909650B1/ko active Active
- 2019-03-13 AU AU2019233581A patent/AU2019233581B2/en active Active
- 2019-03-13 CR CR20200467A patent/CR20200467A/es unknown
- 2019-03-13 WO PCT/EP2019/056252 patent/WO2019175220A1/en not_active Ceased
- 2019-03-13 EP EP19711315.2A patent/EP3765511B1/en active Active
- 2019-03-13 CN CN201980019248.3A patent/CN112020514B/zh active Active
- 2019-03-13 US US16/979,932 patent/US11873341B2/en active Active
- 2019-03-13 CA CA3088671A patent/CA3088671A1/en active Pending
- 2019-03-13 EP EP19710416.9A patent/EP3765507B1/en active Active
- 2019-03-13 BR BR112020016499-2A patent/BR112020016499A2/pt not_active Application Discontinuation
- 2019-03-13 JP JP2020547371A patent/JP7474701B2/ja active Active
- 2019-03-13 MA MA051993A patent/MA51993A/fr unknown
- 2019-03-13 AU AU2019233575A patent/AU2019233575A1/en not_active Abandoned
- 2019-03-13 PE PE2020001299A patent/PE20210288A1/es unknown
- 2019-03-13 WO PCT/EP2019/056256 patent/WO2019175222A1/en not_active Ceased
- 2019-03-13 KR KR1020207029229A patent/KR20200131862A/ko not_active Withdrawn
- 2019-03-13 SG SG11202008699WA patent/SG11202008699WA/en unknown
- 2019-03-13 PE PE2020001292A patent/PE20210287A1/es unknown
- 2019-03-13 JP JP2020547333A patent/JP7510348B2/ja active Active
- 2019-03-13 EP EP19709954.2A patent/EP3765502B1/en active Active
- 2019-03-13 US US16/352,709 patent/US10752691B2/en active Active
- 2019-03-13 SG SG11202008733YA patent/SG11202008733YA/en unknown
- 2019-03-13 CN CN201980019249.8A patent/CN112020515B/zh active Active
- 2019-03-13 US US16/352,717 patent/US10745485B2/en active Active
- 2019-03-13 US US16/979,931 patent/US11851494B2/en active Active
- 2019-03-13 US US16/352,703 patent/US10738125B2/en active Active
- 2019-03-13 TW TW108108467A patent/TW202003034A/zh unknown
- 2019-03-13 JP JP2020547331A patent/JP7563979B2/ja active Active
- 2019-03-13 CA CA3088246A patent/CA3088246A1/en not_active Abandoned
- 2019-03-13 CN CN201980019247.9A patent/CN112020513B/zh active Active
- 2019-03-13 CN CN201980019241.1A patent/CN112020512B/zh active Active
- 2019-03-13 WO PCT/EP2019/056247 patent/WO2019175215A1/en not_active Ceased
- 2019-03-13 AU AU2019233576A patent/AU2019233576A1/en not_active Abandoned
- 2019-03-13 BR BR112020016519-0A patent/BR112020016519A2/pt not_active Application Discontinuation
- 2019-03-13 SG SG11202008784RA patent/SG11202008784RA/en unknown
- 2019-03-13 TW TW108108452A patent/TW201940515A/zh unknown
- 2019-03-13 JP JP2020547415A patent/JP2021515568A/ja active Pending
- 2019-03-13 US US16/979,933 patent/US11919960B2/en active Active
- 2019-03-13 WO PCT/EP2019/056248 patent/WO2019175216A1/en not_active Ceased
- 2019-03-13 WO PCT/EP2019/056257 patent/WO2019175223A1/en not_active Ceased
- 2019-03-13 EP EP19709956.7A patent/EP3765504B1/en active Active
- 2019-03-13 JP JP2020547363A patent/JP7451414B2/ja active Active
- 2019-03-13 TW TW108108451A patent/TW201938588A/zh unknown
- 2019-03-13 JP JP2020547332A patent/JP7565797B2/ja active Active
- 2019-03-13 EP EP19709958.3A patent/EP3765506B1/en active Active
- 2019-03-13 CN CN201980019235.6A patent/CN112041345B/zh active Active
2020
- 2020-02-05 US US16/782,461 patent/US11787866B2/en active Active
- 2020-02-05 US US16/782,440 patent/US11802160B2/en active Active

Also Published As

Publication number	Publication date
BR112020016499A2 (pt)	2021-01-26
JP2021533726A (ja)	2021-12-09
PE20210289A1 (es)	2021-02-11
US20210009699A1 (en)	2021-01-14
BR112020016501A2 (pt)	2021-01-26
JP7563978B2 (ja)	2024-10-08
EP3765504A1 (en)	2021-01-20
US20190322752A1 (en)	2019-10-24
WO2019175223A1 (en)	2019-09-19
US20190300613A1 (en)	2019-10-03
CA3088659A1 (en)	2019-09-19
US10752691B2 (en)	2020-08-25
US11802161B2 (en)	2023-10-31
CN112020513A (zh)	2020-12-01
CN112020512A (zh)	2020-12-01
JP2021515565A (ja)	2021-06-24
US11787866B2 (en)	2023-10-17
EP3765507B1 (en)	2024-04-24
EP3765511C0 (en)	2024-07-24
WO2019175222A1 (en)	2019-09-19
SG11202008699WA (en)	2020-10-29
JP7565797B2 (ja)	2024-10-11
JP2021515566A (ja)	2021-06-24
EP3765506A1 (en)	2021-01-20
WO2019175217A1 (en)	2019-09-19
TW201938588A (zh)	2019-10-01
US11851494B2 (en)	2023-12-26
AU2019233581A1 (en)	2020-09-03
US20200407454A1 (en)	2020-12-31
US20210009704A1 (en)	2021-01-14
US20210040221A1 (en)	2021-02-11
US10745485B2 (en)	2020-08-18
EP3765506B1 (en)	2024-04-24
US11814434B2 (en)	2023-11-14
EP3765506C0 (en)	2024-04-24
US20210009702A1 (en)	2021-01-14
MA51993A (fr)	2021-01-20
US20210054084A1 (en)	2021-02-25
CN112020515B (zh)	2024-07-16
JP7474701B2 (ja)	2024-04-25
CN112020512B (zh)	2024-12-31
KR20200131286A (ko)	2020-11-23
AU2019233576A1 (en)	2020-09-17
SG11202008784RA (en)	2020-10-29
EP3765502A1 (en)	2021-01-20
EP3765504B1 (en)	2024-07-31
EP3765504C0 (en)	2024-07-31
KR20200131862A (ko)	2020-11-24
EP3765511A1 (en)	2021-01-20
EP3765505B1 (en)	2023-09-27
CN112020516B (zh)	2025-01-03
US20190284287A1 (en)	2019-09-19
AU2019233575A1 (en)	2020-09-17
CA3088671A1 (en)	2019-09-19
EP3765502C0 (en)	2024-08-07
US11697688B2 (en)	2023-07-11
US11802160B2 (en)	2023-10-31
JP7510348B2 (ja)	2024-07-03
EP3765505C0 (en)	2023-09-27
CN112074536A (zh)	2020-12-11
EP3765511B1 (en)	2024-07-24
US11919960B2 (en)	2024-03-05
EP3765510A1 (en)	2021-01-20
WO2019175226A1 (en)	2019-09-19
JP2021516974A (ja)	2021-07-15
CN112020516A (zh)	2020-12-01
WO2019175224A1 (en)	2019-09-19
JP2021515568A (ja)	2021-06-24
CR20200465A (es)	2020-11-17
AU2019233581B2 (en)	2025-08-28
US20210047420A1 (en)	2021-02-18
KR20200131861A (ko)	2020-11-24
WO2019175216A1 (en)	2019-09-19
EP3765507A1 (en)	2021-01-20
JP2021516973A (ja)	2021-07-15
US11873341B2 (en)	2024-01-16
WO2019175220A1 (en)	2019-09-19
US20210009703A1 (en)	2021-01-14
EP3765502B1 (en)	2024-08-07
JP7451414B2 (ja)	2024-03-18
JP2021516975A (ja)	2021-07-15
CN112218891A (zh)	2021-01-12
JP2021516976A (ja)	2021-07-15
EP3765503B1 (en)	2024-05-01
TW201940515A (zh)	2019-10-16
CN112074536B (zh)	2024-09-10
CN112020515A (zh)	2020-12-01
CN112020513B (zh)	2024-08-16
PE20210288A1 (es)	2021-02-11
WO2019175215A1 (en)	2019-09-19
EP3765503A1 (en)	2021-01-20
JP7451415B2 (ja)	2024-03-18
KR102909650B1 (ko)	2026-01-08
EP3765503C0 (en)	2024-05-01
CN112020514A (zh)	2020-12-01
EP3765505A1 (en)	2021-01-20
CA3088246A1 (en)	2019-09-19
CR20200466A (es)	2020-11-11
BR112020016519A2 (pt)	2020-12-15
TW202003034A (zh)	2020-01-16
PE20210287A1 (es)	2021-02-11
EP3765507C0 (en)	2024-04-24
JP7563979B2 (ja)	2024-10-08
CN112041345B (zh)	2025-01-03
SG11202008733YA (en)	2020-10-29
CN112020514B (zh)	2024-08-20
CN112218891B (zh)	2024-07-16
CN112041345A (zh)	2020-12-04
US10738125B2 (en)	2020-08-11

Publication	Publication Date	Title
CR20200467A (es)	2020-11-17	Agentes anticuerpos anti-cd25
PH12021550337A1 (en)	2021-10-04	Anti-gdf15 antibodies, compositions and methods of use
EA201792221A1 (ru)	2018-08-31	Антитела против сортилина и способы их применения
EA201992526A1 (ru)	2020-03-13	Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения
EA202092825A1 (ru)	2021-04-22	Анти-sirpa антитела и способы их применения
EA201992402A1 (ru)	2020-02-19	Антитела против ilt4 и антигенсвязывающие фрагменты
SA522431756B1 (ar)	2024-06-09	Tigit أجسام مضادة لـ
CR20200539A (es)	2021-07-01	Receptores quiméricos de dll3 y métodos para su uso
EA201892294A1 (ru)	2019-04-30	Антитела и композиции против tim-3
JOP20190187A1 (ar)	2019-08-01	مترافقات عقار جسم مضاد لـ ccr7
EA202190138A1 (ru)	2021-05-27	Анти-sirp-бета1 антитела и способы их использования
JOP20160131B1 (ar)	2022-03-14	الأجسام المضادة للعامل xi وطرق الاستخدام
PH12020552006A1 (en)	2021-06-14	Antibodies specific for cd3 and uses thereof
GEAP202014437A (en)	2020-06-10	Anti-ctla4 monoclonal antibody or antigen-binding fragment thereof, medicinal composition and use
EA202090944A1 (ru)	2020-07-16	Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
EA201990895A1 (ru)	2019-10-31	Антитела к о1 и варианты их применения
EA202190183A1 (ru)	2021-05-18	Антитела к siglec-5 и способы их применения
MX2024005841A (es)	2024-05-27	Moleculas de union a cd32b x cd79b para usarse como medicamentos para el tratamiento de enfermedades o trastornos inflamatorios y para reducir las respuestas inmunitarias.
ZA202108422B (en)	2026-01-28	Anti-cd25 for tumour specific cell depletion
MX2021003756A (es)	2021-08-11	Composiciones farmaceuticas que comprenden anticuerpos anti cumulo de diferenciacion 37 (cd37) biespecificos.
EA202092279A1 (ru)	2021-02-24	Антитела к mica и/или micb и их применение
AR114277A1 (es)	2020-08-12	Agentes anticuerpos anti-cd25
EA202092151A1 (ru)	2021-02-16	Антитела
EA201992747A1 (ru)	2020-04-21	Антитела к fam19a5 и их применение
EA201992324A1 (ru)	2020-03-10	Анти-trem2 антитела и способы их применения